|
Interferon gamma-1b
resources
|
|
|
|
|
|
DRUG INFO
Interferon gamma-1b
Drug Name:
Interferon gamma-1b
Indication: For treatment of Chronic granulomatous disease, Osteopetrosis
Pharmacology: IFN gamma stimulates expression of the immunoglobulin heavy chain C gamma 3 and C gamma 2a germline transcripts in B cells. Many components of the antigen presentation pathways are also up-regulated by interferon gamma. It is also a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of type I interferons. Interferon gamma may also help the body regulate the activity of fibroblasts. By directly blocking the multiplication of fibroblasts and inhibiting the production and action of TGF-b, a potent scar-inducing molecule, Interferon gamma-1b may prevent excessive scarring.
Mechanism Of Action: Binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 phosphorylation, nuclear translocation and initiation of gene transcription of multiple immune-related genes.
Drug Category: Antiviral Agents; Immunomodulatory Agents
Brand Names/Synonyms: Interferon gamma precursor;IFN-gamma;Immune interferon; Actimmune (InterMune Inc)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human interferon gamma-1b
Chemical Formula: C761H1206N214O225S6
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00017
CAS Registry Number: 82115-62-6; 98059-61-1
|
|
|
|
|
|
Interferon gamma-1b News
(When available)
InterMune to Release Fourth Quarter & Year-End 2005 Financial ... Jan 12, 2006
PR Newswire (press release), The pulmonology portfolio includes Actimmune(R) (interferon gamma-1b), pirfenidone and research programs. Actimmune(R) is being ...
InterMune Completes Divestiture of Infergen(R) for up to $135.5 ... Jan 3, 2006
PR Newswire (press release), ...step in refocusing our corporate strategy to direct resources to our three key development programs -- our Phase III study evaluating Actimmune(R) for ...
Major Inflammatory Systems Linked; Could Make COX-2 Inhibitors ... Jan 9, 2006
Johns Hopkins Gazette, ...in both immune system cells and human embryonic kidney cells by adding substances known to activate these enzymes — for example, LPS-IFN-gamma, a combination ...
|
|
|
